Iida S - Search Results

1

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.

Matsue K, Iwasaki H, Chou T, Tobinai K, Sunami K, Ogawa Y, Kurihara M, Midorikawa S, Zaki M, Doerr T, Iida S. Matsue K, et al. Among authors: iida s. Cancer Sci. 2015 Nov;106(11):1561-7. doi: 10.1111/cas.12772. Epub 2015 Nov 4. Cancer Sci. 2015. PMID: 26292221 Free PMC article. Clinical Trial.

2

Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.

Miura K, Iida S, Hanamura I, Kato M, Banno S, Ishida T, Kusumoto S, Takeuchi G, Miwa H, Nitta M, Inagaki H, Eimoto T, Nomura K, Taniwaki M, Ueda R. Miura K, et al. Among authors: iida s. Cancer Sci. 2003 Apr;94(4):350-4. doi: 10.1111/j.1349-7006.2003.tb01445.x. Cancer Sci. 2003. PMID: 12824903 Free PMC article.

3

Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group.

Shimazaki C, Fujii H, Yoshida T, Chou T, Nishimura M, Asaoku H, Miyawaki S, Ishii A, Ishida T, Taniwaki M, Iida S, Takagi T, Takatsuki K; Japan Myeloma Study Group. Shimazaki C, et al. Among authors: iida s. Int J Hematol. 2005 May;81(4):342-8. doi: 10.1532/IJH97.04174. Int J Hematol. 2005. PMID: 15914367

4

Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.

Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Kajiguchi T, et al. Among authors: iida s. Cancer Sci. 2006 Jun;97(6):540-5. doi: 10.1111/j.1349-7006.2006.00199.x. Cancer Sci. 2006. PMID: 16734734 Free PMC article.

5

Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.

Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Inagaki H, Suzuki A, Ueda R. Yano H, et al. Among authors: iida s. Cancer Sci. 2008 Nov;99(11):2309-14. doi: 10.1111/j.1349-7006.2008.00936.x. Epub 2008 Sep 1. Cancer Sci. 2008. PMID: 18771527 Free PMC article.

6

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sakamaki H, Ishizawa KI, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R. Sakamaki H, et al. Among authors: iida s. Int J Hematol. 2009 Apr;89(3):332-341. doi: 10.1007/s12185-009-0260-2. Epub 2009 Mar 5. Int J Hematol. 2009. PMID: 19263190 Clinical Trial.

7

A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.

Kodama T, Abe M, Iida S, Ozaki S, Sakai A, Sawamura M, Shimazaki C, Miyata A, Wakayama T, Murakami H. Kodama T, et al. Among authors: iida s. Clin Lymphoma Myeloma. 2009 Apr;9(2):154-9. doi: 10.3816/CLM.2009.n.037. Clin Lymphoma Myeloma. 2009. PMID: 19406727

8

[Multiple melanoma-progress in understanding of molecular mechanism and improvement in treatment outcome with introduction of new drugs for multiple myeloma].

Hanamura I, Iida S. Hanamura I, et al. Among authors: iida s. Gan To Kagaku Ryoho. 2010 May;37(5):816-21. Gan To Kagaku Ryoho. 2010. PMID: 20524255 Japanese. No abstract available.

9

Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.

Iida S, Chou T, Okamoto S, Nagai H, Hatake K, Murakami H, Takagi T, Shimizu K, Lau H, Takeshita K, Takatoku M, Hotta T. Iida S, et al. Int J Hematol. 2010 Jul;92(1):118-26. doi: 10.1007/s12185-010-0624-7. Epub 2010 Jun 18. Int J Hematol. 2010. PMID: 20559759 Clinical Trial.

10

Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma.

Grass S, Iida S, Wikowicz A, Preuss KD, Inagaki A, Shimizu K, Ziepert M, Ueda R, Pfreundschuh M. Grass S, et al. Among authors: iida s. Cancer Sci. 2011 Mar;102(3):565-8. doi: 10.1111/j.1349-7006.2010.01819.x. Epub 2011 Jan 25. Cancer Sci. 2011. PMID: 21205072 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,697 results

Search Page

Filters